Insider · CIK 0001778623
Adam M Veness
Files at DNTH (Dianthus Therapeutics, Inc. /DE/). First filing Jun 18, 2026, latest Aug 11, 2026.
In brief
Adam M Veness files SEC Form 4 as officer at DNTH (Dianthus Therapeutics, Inc. /DE/). Since Jun 18, 2026, Adam M Veness has reported 0 open-market buys worth $0 and 2 open-market sells worth $4.6M, the latest filed on Aug 11, 2026.
A track record needs three past buys with six months of prices behind them; Adam M Veness has 0, so none is measured yet.
The newest scored trade: sold $2.2M of DNTH on Aug 7, 2026, filed Aug 11, 2026, scored 40 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $4.6M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DNTH: Dianthus Therapeutics, Inc. /DE/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Dianthus Therapeutics, Inc. /DE/ | $2.2M 20,000 shares | -522% | +481% from low-3% from high | |
| 25Weak | Dianthus Therapeutics, Inc. /DE/ | $2.4M 30,000 shares | -100% | +386% from low-14% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. | 16,167 0.03% of outstanding | $1.8M | Aug 10, 2026 | $2.8M |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. | 3,833 0.01% of outstanding | $421k | Aug 7, 2026 | $2.4M |
| Jun 17, 2026 | DNTH DIANTHUS THERAPEUTICS INC | 30,000 0.05% of outstanding | $2.4M | Jun 17, 2026 | none |
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock | +15,000 | $18.17 | $273k | 15,000 | Aug 14, 2026 |
| Aug 13, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative | -15,000 | $0.00 | $0 | 73,240 | Aug 14, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +3,833 | $17.88 | $69k | 3,833 | Aug 11, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -3,217 | $110.61 | $356k | 616 | Aug 11, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -616 | $111.18 | $68k | 0 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +16,167 | $17.88 | $289k | 16,167 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -16,167 | $110.38 | $1.8M | 0 | Aug 11, 2026 |
| Aug 7, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,833 | $0.00 | $0 | 76,167 | Aug 11, 2026 |
| Aug 10, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,167 | $0.00 | $0 | 60,000 | Aug 11, 2026 |
| Jun 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Common Stock10b5-1 | +30,000 | $17.88 | $536k | 30,000 | Jun 18, 2026 |
| Jun 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -16,771 | $80.34 | $1.3M | 13,229 | Jun 18, 2026 |
| Jun 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | SOpen-market sale Common Stock10b5-1 | -13,229 | $81.38 | $1.1M | 0 | Jun 18, 2026 |
| Jun 17, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 80,000 | Jun 18, 2026 |
| Feb 3, 2026 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 4, 2026 |
| Feb 3, 2025 | DNTH Dianthus Therapeutics, Inc. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 4, 2025 |
Questions about Adam M Veness
Answered from the filings on this page, as of the latest one.
Is Adam M Veness buying or selling?
In the last 12 months Adam M Veness reported 0 open-market buys worth $0 and 2 open-market sells worth $4.6M on SEC Form 4; the latest was sold $2.2M of DNTH on Aug 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Adam M Veness's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Adam M Veness has 0.
Where does Adam M Veness file Form 4?
Adam M Veness has filed Form 4 at DNTH (Dianthus Therapeutics, Inc. /DE/) as SVP, General Counsel and Sec.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.